Serum fetuin-A levels in patients with type 2 diabetes mellitus

Beata Wojtysiak-Duma; Arleta Malecha-Jędraszek; Agata Burska; Dariusz Duma; Helena Donica

doi:10.12923/

Authors

Beata Wojtysiak-Duma Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics Author https://orcid.org/0000-0002-2544-1385
Arleta Malecha-Jędraszek Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics Author https://orcid.org/0000-0002-9104-9760
Agata Burska Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics Author https://orcid.org/0000-0003-3321-9087
Dariusz Duma Department of Laboratory Diagnostics, Medical University of Lublin Author https://orcid.org/0000-0002-5844-9033
Helena Donica Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics Author https://orcid.org/0000-0003-0677-7825

DOI:

https://doi.org/10.12923/

Keywords:

fetuin-A, C-reactive protein, fibrinogen, type 2 diabetes mellitus, macroangiopathies

Abstract

Fetuin-A is a multifunctional circulating glycoprotein that inhibits ectopicvascular calcification and induces insulin resistance in animals and humans. Low fetuin-A levels in dialysed patients are associated with cardiovascular mortality due to accelerating vascular calcification. The most serious complications of diabetes are atherosclerotic heart disease, cerebrovascular disease, and renal disease. The most common cause of death with diabetes mellitus is myocardial infarction. In this work we determined serum concentration of fetuin-A to elucidate its role in the development of cardiovascular complications in diabetic patients. We studied 51 patients with type 2 diabetes mellitus and 30 healthy humans. Macrovascular complications were present in 30 and microvascular in 19 diabetic patients. In these groups we determined serum concentration of fetuin-A, fibrinogen, CRP, total cholesterol, triglicerydes, cholesterol HDL and LDL. We found that serum levels of fetuin-A were decreased in the group of diabetic patients compared to control subjects. In patients with low fetuin-A concentration (below 22.44 ng/L) high levels of C-reactive protein (>5 mg/L) were found in 56 % and high concentration of fibrinogen (>4 g/L) in 75% of cases. In the group of patients with all of three risk factors the frequency of macrovascular complications was 100%. Our data suggest that fetuin-A is an independent risk factor of the development of macrovascular but not microvascular complications in type 2 diabetes mellitus patients. We concluded that determination of serum fetuin concentration together with high sensitivity CRP and fibrinogen levels may be a useful indicator of pending pathological process in cardiovascular system.

References

1. Emoto M., Mori K., Lee E. et al.: Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metab. Clin. Exp., 59, 873, 2010.

2. Eraso L.H., Ginwala N., Qasim A.N. et al.: Association of lower plasma fetuin-A levels with peripheral arterial disease in type 2 diabetes. Diabetes Care, 33, 408, 2010.

3. Fisher E., Stefan N., Saar K. et al.: Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ. Cardiovasc. Genet., 2, 607, 2009.

4. Ix J.H., Shlipak M.G., Brandenburg V.M. et al.: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation, 113, 1760, 2006.

5. Kaushik S.V., Plaisance E.P., Kim T. et al.: Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab. Res. Rev., 25, 427, 2009.

6. Ketteler M.: Fetuin-A and extraosseous calcification in uremia. Curr. Opin. Nephrol. Hypertens., 14, 337, 2005.

7. Ketteler M., Bongartz P., Westenfeld R. et al.: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a crosssectional study. Lancet, 361, 827, 2003.

8. Mehrotra R., Westenfeld R., Christenson P. et al.: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int., 67, 1070, 2005.

9. Reynolds J.L., Skepper J.N., McNair R. et al.: Multifunctional roles for serum protein fetuin-A in inhibiton of human vascular smooth muscle cell calcification. J. Am. Soc. Nephrol., 16, 2920, 2005.

10. Schäfer C., Heiss A., Schwarz A. et al.: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin. Invest., 112, 357, 2003.

11. Stefan N., Fritsche A., Weikert C. et al.: Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes, 57, 2762, 2008.

12. Stenvinkel P., Wang K., Axelsson J. et al.: Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int., 67, 2383, 2005.

13. Streja D., Cresseya P., Rabkinb S.W.: Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J. Diabetes Complications, 17, 120, 2003.

14. Wang A.Y., Woo J., Lam C.W. et al.: Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol. Dial. Transplant., 20,1676, 2005.

15. Westenfeld R., Jahnen-Dechent W., Ketteler M.: Vascular Calcification and Fetuin-A Deficiency in Chronic Kidney Disease. Trends Cardiovasc. Med., 17, 124, 2007.

Serum fetuin-A levels in patients with type 2 diabetes mellitus

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

Issue

Section

License

sidebar

Language